181 related articles for article (PubMed ID: 31524156)
1. Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease.
Patra K; Giannisis A; Edlund AK; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Nielsen HM
J Alzheimers Dis; 2019; 71(4):1217-1231. PubMed ID: 31524156
[TBL] [Abstract][Full Text] [Related]
2. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
[TBL] [Abstract][Full Text] [Related]
3. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
4. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
5. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
[TBL] [Abstract][Full Text] [Related]
6. Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
Dunk MM; Driscoll I;
J Alzheimers Dis; 2022; 85(4):1519-1528. PubMed ID: 34958023
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
8. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
[TBL] [Abstract][Full Text] [Related]
10. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
[TBL] [Abstract][Full Text] [Related]
13. Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism.
Nielsen HM; Chen K; Lee W; Chen Y; Bauer RJ; Reiman E; Caselli R; Bu G
Alzheimers Res Ther; 2017 Jan; 9(1):5. PubMed ID: 28137305
[TBL] [Abstract][Full Text] [Related]
14. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
Wang S; Zhang J; Pan T;
Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
[TBL] [Abstract][Full Text] [Related]
15. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
16. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
17. Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population.
Monge-Argilés JA; Gasparini-Berenguer R; Gutierrez-Agulló M; Muñoz-Ruiz C; Sánchez-Payá J; Leiva-Santana C
Biomed Res Int; 2016; 2016():1390620. PubMed ID: 27092308
[TBL] [Abstract][Full Text] [Related]
18. Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study.
Shi J; Leporé N; Gutman BA; Thompson PM; Baxter LC; Caselli RJ; Wang Y;
Hum Brain Mapp; 2014 Aug; 35(8):3903-18. PubMed ID: 24453132
[TBL] [Abstract][Full Text] [Related]
19. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Wattmo C; Blennow K; Hansson O
BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
[TBL] [Abstract][Full Text] [Related]
20. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
